A study to learn how the study medicine called [14C]PF-07054894 is processed by the body.

2024-519882-23-00 Protocol C4151008 Human pharmacology (Phase I) - Other Ended

Start 13 Jun 2025 · End 12 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol C4151008

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 10
Countries 1
Sites 1

Inflammatory bowel disease.

Key facts

Sponsor
Pfizer Inc.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
13 Jun 2025 → 12 Sep 2025
Decision date (initial)
2025-05-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-519882-23-00
ClinicalTrials.gov
NCT05549323

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Inflammatory bowel disease.

VersionLevelCodeTermSystem organ class
20.1 LLT 10045365 Ulcerative colitis 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation
Pfizer Inc.
Address
66 Hudson Boulevard East
City
New York
Postcode
10001-2189
Country
United States

Scientific contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Pfizer Inc.
Contact name
Clinical Medical Lead

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 10 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-06-13 2025-09-11 2025-06-20 2025-07-18

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-10 Netherlands Acceptable
2025-05-15
2025-05-15